BPC-157

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide composed of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It is derived from a naturally occurring protein found in human gastric juice. First identified and characterized by researchers at the University of Zagreb under the leadership of Professor Predrag Sikiric, BPC-157 has been the subject of numerous preclinical studies examining its potential tissue-protective and regenerative effects.

## Mechanism of Action

BPC-157 exerts its effects through multiple interconnected molecular pathways. A central mechanism involves the nitric oxide (NO) system — BPC-157 modulates NO synthesis and interacts with both the constitutive (eNOS) and inducible (iNOS) nitric oxide synthase pathways, which play critical roles in vascular function, inflammation, and tissue repair. The peptide also activates the FAK-paxillin signaling pathway, a key regulator of cell migration, adhesion, and survival that is essential for wound healing. Research has demonstrated that BPC-157 upregulates multiple growth factors, including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and transforming growth factor beta (TGF-b), promoting angiogenesis and tissue regeneration. Additionally, BPC-157 appears to influence the GH-IGF-1 axis and interact with the dopaminergic, serotonergic, and GABAergic neurotransmitter systems, which may account for its reported effects on mood and neuroprotection.

## Research in Tissue Healing

Research in animal models has demonstrated that BPC-157 may promote healing of a wide variety of tissues, including tendons, ligaments, muscles, the gastrointestinal tract, and even bone. Studies have shown it can counteract the damaging effects of NSAIDs on the gut lining and accelerate the healing of gastric ulcers in rodent models. In tendon injury models, BPC-157 accelerated the healing of transected Achilles tendons with improved biomechanical properties. Muscle crush injury studies demonstrated earlier return of function markers. Bone fracture healing studies showed enhanced callus formation and improved bone density at fracture sites.

## Neuroprotective Effects

One of the most notable aspects of BPC-157 research is its apparent systemic protective effect. Animal studies suggest it may protect organs from damage caused by various toxic agents, support nerve healing, and influence neurotransmitter systems including dopamine and serotonin pathways. Research has shown BPC-157 can counteract both the acute and chronic effects of dopaminergic system disturbances, protect against serotonin syndrome, and promote peripheral nerve regeneration after transection injuries. Studies in the central nervous system have demonstrated potential protective effects against traumatic brain injury, stroke, and neurotoxic agents.

## Dosing Protocols (Research/Anecdotal)

No officially approved dosing protocol exists for humans. The following protocols are derived from anecdotal reports and practitioner guidance in the research community:

- **Standard Protocol**: 250-500 mcg subcutaneously, once or twice daily, for 4-6 weeks. This is the most commonly reported regimen for general tissue support. - **Aggressive Protocol**: 500-750 mcg subcutaneously, twice daily, for 2-4 weeks. Reported in cases of acute injury or significant tissue damage. - **Maintenance Protocol**: 150-250 mcg subcutaneously, once daily or every other day. Used as a follow-up after an initial treatment course. - **Loading Protocol**: 750 mcg subcutaneously, twice daily, for 7-10 days followed by step-down to standard dosing. Reported for severe acute injuries.

## Reconstitution Guide

BPC-157 is supplied as a lyophilized (freeze-dried) powder that must be reconstituted before injection:

- **5 mg vial with 2 mL bacteriostatic water**: Each 0.1 mL (10 units on an insulin syringe) = 250 mcg. Draw 0.1 mL for a 250 mcg dose or 0.2 mL for a 500 mcg dose. - **10 mg vial with 2 mL bacteriostatic water**: Each 0.1 mL = 500 mcg. Draw 0.05 mL (5 units) for a 250 mcg dose or 0.1 mL for a 500 mcg dose. - Inject bacteriostatic water slowly along the vial wall; do not shake. Gently swirl until fully dissolved. Solution should be clear and colorless.

## Storage Requirements

- **Lyophilized (unreconstituted)**: Store at -20 degrees C for long-term storage; stable at room temperature for short periods during shipping. - **Reconstituted**: Refrigerate at 2-8 degrees C. Use within 28 days of reconstitution. Do not freeze reconstituted solution. Protect from light.

## Administration Routes

- **Subcutaneous injection**: Most common route. Inject near the site of injury when possible for localized effects, or into abdominal fat for systemic effects. - **Intramuscular injection**: Used for deeper tissue injuries. Less common but reported in some protocols. - **Oral (BPC-157 ARGININE salt)**: A stable oral form has been developed using the arginine salt of BPC-157. This form is particularly studied for gastrointestinal applications (ulcers, inflammatory bowel conditions, NSAID damage). The arginine salt provides stability in gastric acid, allowing oral bioavailability. Typical oral research doses range from 250-500 mcg.

## Drug Interactions and Contraindications

BPC-157 may interact with medications that affect the nitric oxide system (such as PDE5 inhibitors like sildenafil), growth factor pathways, or the dopaminergic system. Caution is advised when combining BPC-157 with anticoagulants due to its effects on angiogenesis and vascular function. Individuals with active cancer should avoid BPC-157 due to its pro-angiogenic properties — enhanced blood vessel formation could theoretically support tumor growth. Pregnant or breastfeeding individuals should not use BPC-157 due to the absence of reproductive safety data.

## 2026 Regulatory Status

As of February 27, 2026, the FDA finalized its Category 1 reclassification of BPC-157, placing it on the list of bulk drug substances that cannot be used by compounding pharmacies under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This effectively ended the legal compounding of BPC-157 in the United States, significantly impacting availability through previously legitimate channels. The FDA cited the lack of adequate safety and efficacy data from controlled human clinical trials as the primary rationale.

## International Legal Status

- **United States**: Not FDA-approved. As of Feb 2026, cannot be compounded under 503A/503B. Available only as a research chemical. The FDA has issued multiple warning letters to companies marketing BPC-157 for human use. - **United Kingdom**: Not approved by the MHRA. Available as a research chemical. No specific prohibition on personal importation for research. - **European Union**: Not approved by the EMA. Regulatory status varies by member state. Generally available as a research compound. - **Australia**: Listed as a Schedule 4 (prescription-only) substance by the TGA. Cannot be legally obtained without a prescription. Importation for personal use is restricted. - **Canada**: Not approved by Health Canada. Available through some compounding pharmacies and as a research chemical. Regulatory enforcement is evolving. - **WADA**: BPC-157 is not currently explicitly listed by the World Anti-Doping Agency, though its use may fall under the general prohibition of peptide hormones and growth factors in competitive athletics.

## Cost Context

Pricing for research-grade BPC-157 varies significantly by source and form. Typical ranges (as of 2026): lyophilized powder 5 mg vials range from $25-60 USD from research chemical suppliers; 10 mg vials from $40-100 USD. Compounded injectable preparations (where still available internationally) range from $100-250 per vial through licensed pharmacies. Oral BPC-157 arginine salt capsules are typically $50-120 for a 30-day supply. Prices vary substantially based on purity, third-party testing, and source reputation.

Despite the absence of robust human clinical data, BPC-157 has become one of the most popular peptides in the wellness and biohacking communities. Its widespread use is driven largely by anecdotal reports and the breadth of positive preclinical findings. Researchers continue to investigate its mechanisms and therapeutic potential, but consumers should exercise caution and recognize that animal study results do not always translate to humans.

## Key PubMed References

[1] Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157. Gastrointestinal tract, hepatopancreatic and brain current knowledge." J Physiol Paris. 1999;93(6):505-10. PMID: 10672982

[2] Seiwerth S, et al. "BPC 157's effect on healing." J Pharmacol Sci. 2018;138(3):168-175. PMID: 30449450

[3] Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Orthop Res. 2011;29(11):1887-93. PMID: 21547975

[4] Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Med Sci Monit. 2010;16(3):BR81-88. PMID: 19917281

[5] Vukojevic J, et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regen Res. 2022;17(3):482-487. PMID: 34380876